Answers are grounded in this paper and cite their sources.
Prostate cancer progression is critically dependent on androgen receptor (AR) signaling. The W741L substitution in the AR ligand-binding domain (AR-LBD), arising during bicalutamide treatment and converting the drug from an antagonist to an agonist, represents a key resistance mechanism in castration-resistant prostate cancer (CRPC). An integrated in silico workflow was applied to identify natural product-derived candidates targeting this resistance-associated conformation using the W741L mutant AR-LBD crystal structure (PDB ID: 1Z95). From 695,133 COCONUT database compounds, 185,124 drug-like candidates were selected by physicochemical and AR-oriented filtering and subjected to large-scale molecular docking. Protocol validation by bicalutamide redocking yielded an RMSD of 1.23 Å and a docking score of −10.01 kcal/mol, confirming accurate reproduction of the crystallographic binding mode. Lig_14814 emerged as the top-ranked docking hit (−12.29 kcal/mol), forming hydrogen bonds, π–π, π–sulfur, and hydrophobic interactions within the AR binding pocket. ADME evaluation confirmed Lipinski compliance and high gastrointestinal absorption. Molecular dynamics simulations (100 ns) demonstrated stability comparable to the reference, with similar RMSD, hydrogen-bond occupancy, and SASA profiles. DFT calculations (B3LYP-D3BJ/def2-SVP/CPCM) revealed a larger HOMO–LUMO gap (0.5160 vs 0.4138 eV), higher chemical hardness (0.2580 vs 0.2069 eV), and lower electrophilicity (66.30 vs 95.47 eV) for Lig_14814, indicating enhanced electronic stability. Machine learning models achieved ROC–AUC >0.92 as docking surrogates, with precision–recall analysis adopted as the primary performance measure given the 16.5:1 class imbalance, while SHAP analysis identified aromatic and carbon–oxygen fragments as principal structural determinants. These findings identify Lig_14814 as a promising natural product-derived scaffold warranting experimental validation against bicalutamide-resistant CRPC.
No takes yet. Share an insight, caveat, or question.
Aktaş et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: